Gofar Stock(SH:600538) Xin Lang Cai Jing·2026-02-23 08:37Core Viewpoint - The company has released a special announcement regarding its performance forecast for 2025, indicating expected revenue of approximately 330 million yuan and a net loss attributable to the parent company of 85 million yuan, along with a planned goodwill impairment provision of about 62.45 million yuan [1]. Group 1: Revenue and Profitability - The company expects to achieve an operating revenue of 329.56 million yuan for 2025, with a net profit of -8.5 million yuan after deducting unrelated business income [1]. - The pharmaceutical distribution business is projected to generate 190.72 million yuan in revenue, accounting for 57.87% of total revenue, with a year-on-year growth of 4.43% [2]. - The revenue from the pharmaceutical distribution business is primarily driven by increased sales from centralized procurement and narcotic drugs, with centralized procurement revenue growing by 56% to 17.33 million yuan [2]. Group 2: Business Segment Performance - The pharmaceutical manufacturing segment is expected to generate 27.14 million yuan, reflecting a year-on-year decline of 23.44% due to maintenance of the eye drop production line and sales policy optimization [3]. - The IVD business is projected to generate 106.85 million yuan, down 10% year-on-year due to reduced executable orders and intensified market competition [3]. - Other business revenues increased by 32.74% to 4.84 million yuan, mainly driven by growth in consulting service fees [3]. Group 3: Market Context and Comparisons - The growth in the pharmaceutical distribution business aligns with regional market demand and industry trends, with the total drug sales in the Beibu Gulf region expected to grow by 4.0%-4.5% in 2025 [4]. - The company’s revenue growth rate is in line with comparable companies in the industry, such as Jiuzhoutong and Sinopharm, which reported revenue growth rates of 5.2% and 3.56% respectively [4]. - The distribution of revenue across quarters is balanced, with no significant concentration of revenue recognition at the end of the period [4]. Group 4: Goodwill Impairment - The company plans to recognize a goodwill impairment of 62.45 million yuan due to ongoing performance pressure from the acquisition of Guangzhou Gaoshen Biotechnology Co., which has seen a decline in revenue and profit since 2023 [5]. - The revenue realization rate for the acquired business is only 42.25%, with net profit realization at -2.39%, attributed to budget cuts from police clients and increased market competition [5]. - The company has previously recognized goodwill impairments of 55 million yuan and 60 million yuan in 2023 and 2024, respectively, with a remaining goodwill balance of 138 million yuan by the end of 2024 [5].